肠道菌群预测黑色素瘤患者免疫治疗反应 | 热心肠日报
预测转移性黑色素瘤中，对肠道微生物群预测癌症免疫治疗反应的荟萃分析
10.1172/jci.insight.140940
12-03, Article
Abstract & Authors:展开
Abstract:收起
BACKGROUND: Identifying factors conferring responses to therapy in cancer is critical to select the best treatment for patients. For immune checkpoint inhibition (ICI) therapy, mounting evidence suggests that the gut microbiome can determine patient treatment outcomes. However, the extent to which gut microbial features are applicable across different patient cohorts has not been extensively explored.
METHODS: We performed a meta-analysis of 4 published shotgun metagenomic studies (Ntot = 130 patients) investigating differential microbiome composition and imputed metabolic function between responders and nonresponders to ICI.
RESULTS: Our analysis identified both known microbial features enriched in responders, such as Faecalibacterium as the prevailing taxa, as well as additional features, including overrepresentation of Barnesiella intestinihominis and the components of vitamin B metabolism. A classifier designed to predict responders based on these features identified responders in an independent cohort of 27 patients with the area under the receiver operating characteristic curve of 0.625 (95% CI: 0.348–0.899) and was predictive of prognosis (HR = 0.35, P = 0.081).
CONCLUSION: These results suggest the existence of a fecal microbiome signature inherent across responders that may be exploited for diagnostic or therapeutic purposes.
First Authors:
Angelo Limeta
Correspondence Authors:
Jens Nielsen
All Authors:
Angelo Limeta,Boyang Ji,Max Levin,Francesco Gatto,Jens Nielsen